# Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

> **NCT06911944** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Michael Rafii, MD, PhD** · enrollment: 60 (estimated)

## Conditions studied

- Down Syndrome (DS)
- Down Syndrome (Trisomy 21)
- Alzheimer Disease
- Amyloid Beta Protein

## Interventions

- **DRUG:** Donanemab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06911944
- **Lead sponsor:** Michael Rafii, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911944, "Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06911944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*